中关村：盐酸阿罗洛尔片上市许可申请获受理

Core Viewpoint - The announcement indicates that Beijing Huasu has received acceptance for the marketing authorization application of its product, Arolol Hydrochloride Tablets, which could positively impact the company's financial performance if approved [1] Group 1: Company Information - Beijing Huasu's Arolol Hydrochloride Tablets (10mg) are an α-β receptor blocker used for treating primary hypertension, angina pectoris, tachyarrhythmia, and essential tremor [1] - The project has incurred a total R&D expense of 6.09 million yuan [1] Group 2: Market Context - Currently, three generic versions of Arolol Hydrochloride Tablets have been approved for sale in the domestic market [1] - In addition to Beijing Huasu, four other domestic companies have submitted marketing authorization applications, which are currently under review [1]